Compare Anza Therapeutics vs NovaDigm Therapeutics
Customers evaluate the quality of Anza Therapeutics's products using the following success metrics.
Overview
Anza Therapeutics is based in United States
Anza Therapeutics is developing active immunotherapies for the treatment of infectious diseases and cancer. Anza's therapeutic agents are based on its proprietary live-attenuated and Killed But Metabolically Active (KBMA) Listeria platforms which can be engineered to express antigens specific to the disease being treated.
NovaDigm Therapeutics is based in United States
NovaDigm Therapeutics is developing vaccines to protect patients from fungal and bacterial infections, which can be life-threatening and drug resistant. The company's lead product candidate, NDV-3, is a recombinant glycoprotein vaccine containing a candidal surface antigen, agglutinin-like sequence 3 protein or Als3. Results from a Phase 1 clinical trial demonstrated that a single dose of the NDV-3 vaccine was safe, well-tolerated and induced strong antibody and T-cell immune responses in healthy adults.
Demo Video
Leadership
David Cook (President)
John E Edwards (Founder)
Funding
Investors
Sofinnova Partners and Kleiner Perkins Caufield & Byers
Domain Associates
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Anza Therapeutics has not claimed their profile.
Work for Anza Therapeutics? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Anza Therapeutics?
Claim your profile now.
Information not available because NovaDigm Therapeutics has not claimed their profile.
Work for NovaDigm Therapeutics? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for NovaDigm Therapeutics?
Claim your profile now.